Envista Announces Participation in 43rd Annual J.P. Morgan Healthcare Conference

1/7/25 4:10:00 PM ET

Medical/Dental Instruments

Health Care

Get the next $NVST alert in real time by email

BREA, Calif., Jan. 7, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") today announced that the company will participate in a presentation at the 43^rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, from 9:45 – 10:25 am PT at the Westin St. Francis Hotel in San Francisco. There will be an audio-only recording link that can be viewed on Envista's Investor Relations website for up to 30 days following the event.

ABOUT ENVISTA HOLDINGS CORPORATION

Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by a shared purpose: to partner with professionals to improve lives. Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services. Its comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide array of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile. With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, Envista is well equipped to meet the end-to-end needs of dental professionals worldwide. Envista is one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry. For more information, please visit www.envistaco.com.

FOR FURTHER INFORMATION

James Gustafson

Vice President, Investor Relations

Envista Holdings Corporation

200 S. Kraemer Blvd., Building E

Brea, CA 92821

Telephone: (714) 817-7000

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/envista-announces-participation-in-43rd-annual-jp-morgan-healthcare-conference-302344979.html

SOURCE Envista Holdings Corporation

Get the next $NVST alert in real time by email

Recent Analyst Ratings for

$NVST

Date	Price Target	Rating	Analyst
5/27/2025	$23.00	Neutral → Outperform	Robert W. Baird
12/4/2024	$20.00	Underperform	Mizuho
10/31/2024	$16.00 → $23.00	Underperform → Market Perform	Leerink Partners
10/8/2024	$20.00	Equal Weight	Wells Fargo
8/8/2024	$23.00 → $16.00	Overweight → Neutral	JP Morgan
4/26/2024	$33.00 → $21.00	Overweight → Equal-Weight	Morgan Stanley
2/26/2024	$19.00	Underperform	Leerink Partners
2/9/2024	$30.00 → $23.00	Buy → Hold	Jefferies

More analyst ratings

Envista Announces Participation in 43rd Annual J.P. Morgan Healthcare Conference

Chat with this insight

Recent Analyst Ratings for
$NVST

$NVST
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Envista upgraded by Robert W. Baird with a new price target

Mizuho initiated coverage on Envista with a new price target

Envista upgraded by Leerink Partners with a new price target

$NVST
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Keel Paul A bought $506,100 worth of shares (30,000 units at $16.87), increasing direct ownership by 8% to 402,605 units (SEC Form 4)

Chief Financial Officer Hammes Eric D. bought $400,608 worth of shares (24,532 units at $16.33) (SEC Form 4)

Conley Eric bought $50,015 worth of shares (2,185 units at $22.89), increasing direct ownership by 5% to 47,376 units (SEC Form 4)

$NVST
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Gallahue Kieran was granted 10,450 shares, increasing direct ownership by 31% to 44,680 units (SEC Form 4)

Director Raskas Daniel was granted 10,450 shares, increasing direct ownership by 31% to 44,680 units (SEC Form 4)

Director Jain Vivek was granted 10,450 shares, increasing direct ownership by 32% to 43,615 units (SEC Form 4)

Envista Announces Participation in 43rd Annual J.P. Morgan Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $NVST

$NVST Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Envista upgraded by Robert W. Baird with a new price target

Mizuho initiated coverage on Envista with a new price target

Envista upgraded by Leerink Partners with a new price target

$NVST Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Keel Paul A bought $506,100 worth of shares (30,000 units at $16.87), increasing direct ownership by 8% to 402,605 units (SEC Form 4)

Chief Financial Officer Hammes Eric D. bought $400,608 worth of shares (24,532 units at $16.33) (SEC Form 4)

Conley Eric bought $50,015 worth of shares (2,185 units at $22.89), increasing direct ownership by 5% to 47,376 units (SEC Form 4)

$NVST Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Gallahue Kieran was granted 10,450 shares, increasing direct ownership by 31% to 44,680 units (SEC Form 4)

Director Raskas Daniel was granted 10,450 shares, increasing direct ownership by 31% to 44,680 units (SEC Form 4)

Director Jain Vivek was granted 10,450 shares, increasing direct ownership by 32% to 43,615 units (SEC Form 4)

Recent Analyst Ratings for
$NVST

$NVST
Analyst Ratings

$NVST
Insider Purchases

$NVST
Insider Trading